#### FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC–5301, Washington, DC 20024, (202) 326–3100.

By direction of the Commission.

#### Donald S. Clark,

Secretary.

[FR Doc. 2017–07541 Filed 4–13–17; 8:45 am] BILLING CODE 6750–01–P

## GULF COAST ECOSYSTEM RESTORATION COUNCIL

[Docket Number: 104142017-1111-11]

#### Notice of Proposed Subaward Under a Council-Selected Restoration Component Award

**AGENCY:** Gulf Coast Ecosystem Restoration Council.

**ACTION:** Notice; correction.

SUMMARY: The Gulf Coast Ecosystem
Restoration Council (Council) published
a document in the Federal Register on
March 14, 2017 to provide notice of a
proposed subaward from the National
Oceanic and Atmospheric
Administration (NOAA) to the Gulf of
Mexico Alliance (GOMA), a nonprofit
organization for the purpose of

Mexico Alliance (GOMA), a nonprofit organization, for the purpose of supporting the Council Monitoring and Assessment Program (CMAP) in accordance with the Council Monitoring & Assessment Program Development award as approved in the Initial Funded Priority List. The March 14, 2017 notice did not include the amount of the proposed subaward. Through this correction, the Council publishes the amount of the proposed subaward.

#### FOR FURTHER INFORMATION CONTACT:

Please send questions by email to raams\_pgmsupport@restorethegulf.gov.

**SUPPLEMENTARY INFORMATION: Section** 1321(t)(2)(E)(ii)(III) of the RESTORE Act (33 U.S.C. 1321(t)(2)(E)(ii)(III)) and Treasury's implementing regulation at 31 CFR 34.401(b) require that, for purposes of awards made under the Council-Selected Restoration Component, a State or Federal award recipient may make a grant or subaward to or enter into a cooperative agreement with a nongovernmental entity that equals or exceeds 10 percent of the total amount of the award provided to the State or Federal award recipient only if certain notice requirements are met. Specifically, at least 30 days before the State or Federal award recipient enters into such an agreement, the Council must publish in the Federal Register and deliver to specified Congressional

Committees the name of the recipient and subrecipient; a brief description of the activity, including its purpose; and the amount of the award.

In the **Federal Register** notice of March 14, 2017, at 82 FR 13607, the Council provided notice of a proposed subaward from NOAA to GOMA for the purpose of supporting CMAP in accordance with the Council Monitoring & Assessment Program Development award; however, the March 14, 2017 notice inadvertently omitted the amount of the proposed subaward to GOMA. The amount of the proposed subaward from NOAA to GOMA under the Council Monitoring & Assessment Program Development award is \$525,000.

#### Will D. Spoon,

Program Analyst, Gulf Coast Ecosystem Restoration Council.

[FR Doc. 2017-07562 Filed 4-13-17; 8:45 am]

BILLING CODE 6560-58-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

[CDC-2015-0020; Docket Number NIOSH 156-A]

## Issuance of Final Guidance Publications

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of issuance of final guidance publications.

SUMMARY: NIOSH announces the availability of the following final 14 IDLH Value Profiles: Iron Pentacarbonyl, Acrylonitrile, 1,1-Dichloro-1-Fluoroethane (HCFC-141b), Chloroacetyl Chloride, Chlorine Pentafluoride, Furan, Hexafluoroacetone, n-Butyl Acrylate, Benzontrile, Methyl Isocyanate, Bromine Pentafluoride, 1,3-Butadiene, Diketene and Butane.

**DATES:** The final IDLH documents were published on October 5 and December 16, 2016.

**ADDRESSES:** These documents may be obtained at the following links:

- Iron Pentacarbonyl: https:// www.cdc.gov/niosh/docs/2016-166/
- Acrylonitrile: https://www.cdc.gov/ niosh/docs/2016-167/

- 1,1-Dichloro-1-Fluoroethane (HCFC– 141b): https://www.cdc.gov/niosh/ docs/2016-168/
- Chloroacetyl Chloride: https://www.cdc.gov/niosh/docs/2016-169/
- Chlorine Pentafluoride: https:// www.cdc.gov/niosh/docs/2016-170/
- Furan: https://www.cdc.gov/niosh/docs/2016-171/
- Hexafluoroacetone: https:// www.cdc.gov/niosh/docs/2016-172/
- n-Butyl Acrylate: https:// www.cdc.gov/niosh/docs/2016-173/
- Butane: https://www.cdc.gov/niosh/ docs/2016-174/
- Benzontrile: https://www.cdc.gov/ niosh/docs/2017-104/
- Methyl Isocynate: https:// www.cdc.gov/niosh/docs/2017-105/
- Bromine Pentafluoride: https:// www.cdc.gov/niosh/docs/2017-106/
- 1,3-Butadiene: https://www.cdc.gov/ niosh/docs/2017-107/
- Diketene: https://www.cdc.gov/niosh/ docs/2017-108/

# **FOR FURTHER INFORMATION CONTACT:** G. Scott Dotson, NIOSH/Education and Information Division, 1090 Tusculum Ave., MS C–32, Cincinnati, OH 45226, email address: *fya8@cdc.gov*.

SUPPLEMENTARY INFORMATION: On May 1, 2015, NIOSH published a request for public review in the Federal Register [80 FR 24930] on immediately dangerous to life and health (IDLH) values and support technical documents. All comments received were reviewed and accepted where appropriate.

#### John Howard,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2017–07523 Filed 4–13–17; 8:45 am]

BILLING CODE 4163-19-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcement (FOA) GH17–002, Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the Presidents Emergency Plan for AIDS Relief (PEPFAR); GH17–003,

Conducting Public Health Research in South Africa; GH17–004, Conducting Public Health Research Activities in Egypt.

Summary: This publication corrects a notice that was published in the **Federal Register** on April 4, 2017, Volume 82, Number 63, page 16403. The meeting announcement, meeting date, and matters for discussion should read as follows:

The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcements GH17–002, Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the President's Emergency Plan for AIDS Relief (PEPFAR); and GH17–003, Conducting Public Health Research in South Africa.

Time and Date: 9:00 a.m.–2:00 p.m., EDT, April 25, 2017, Panel A (Closed).

Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to "Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the President's Emergency Plan for AIDS Relief (PEPFAR)", FOA GH17–002; and "Conducting Public Health Research in South Africa", FOA GH17–003.

For Further Information Contact: Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road NE., Mailstop D–69, Atlanta, Georgia 30033, Telephone: (404) 639–4796, HSHOOB@CDC.GOV.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2017–07595 Filed 4–13–17; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

## Health Resources and Services Administration

## CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) announce the following committee meeting.

Times and Dates: 8:30 a.m.–5:00 p.m., EDT, May 10, 2017; 8:30 a.m.–3:00 p.m., EDT, May 11, 2017.

Place: CDC Corporate Square, Building 8, Conference Room 1–ABC, 8 Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639–8317. The meeting is also accessible by teleconference. Toll-free number 1–877– 603–4228, Participant code: 42598858.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 100 people. Persons who desire to make an oral statement, may request it at the time of the public comment period on May 10, 2017 at 4:30 p.m., EDT. Public participation and ability to comment will be limited to space and time as it permits.

Purpose: This committee is charged with advising the Director, CDC and the Administrator, HRSA, regarding activities related to prevention and control of HIV/AIDS, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV/AIDS, and education of health professionals and the public about HIV/AIDS, Viral Hepatitis and other STDs.

Matters for Discussion: Agenda items include the following topics: (1) HIV transmission risk in the context of viral suppression and antiretroviral therapy (ART) use; (2) Update on Pre-Exposure Prophylaxis (PrEP) utilization; (3) Vulnerable youth at risk for HIV, STDs, hepatitis, substance use and other health outcomes; (4) Eliminating hepatitis B and hepatitis C as public health threats in the United States—Setting Goals and Taking Action; and (5) Updates from Workgroups. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Margie Scott-Cseh, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop E–07, Atlanta, Georgia 30329, telephone (404) 639–8317; Email: *zkr7@cdc.gov.* 

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2017–07593 Filed 4–13–17; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

#### Healthcare Infection Control Practices Advisory Committee (HICPAC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) announces a meeting of the aforementioned committee:

*Time and Date:* 1:00 p.m.–2:30 p.m., EDT, May 5, 2017.

Place: This meeting will be accessible by teleconference. Toll-free +1 (888) 469–1070, Participant Code: 3132529.

Status: Open to the public limited only by the availability of 200 telephone ports. To register for this call, please go to www.cdc.gov/hicpac.

Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, the Secretary, Health and Human Services regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

Matters for Discussion: The agenda will include a follow-up discussion on the Draft Recommendation Update for Chlorhexidine Impregnated Dressings. Call materials will be made available to the public no later than 2 business days